The cost of Dupixent (dupilumab) in the USA varies depending on factors such as insurance coverage, dosage, and pharmacy. Without insurance, the list price for a 300 mg vial of Dupixent can range from approximately $3,700 to over $4,000 per month. However, many patients utilize manufacturer copay programs, patient assistance programs, or have insurance that significantly reduces their out-of-pocket expenses.
How much does Dupixent cost per month with insurance?
With commercial insurance, out-of-pocket costs for Dupixent can range from $10 to $130 per month, depending on the specific insurance plan and its formulary. For individuals with Medicare Part D, the cost can vary widely based on the plan's coverage and the patient's benefit stage, potentially ranging from around $130 to over $500 per month. Medicaid coverage for Dupixent also varies by state, and patients may have little to no out-of-pocket cost if covered.
What financial assistance programs are available for Dupixent?
Sanofi Genzyme, the manufacturer of Dupixent, offers several financial assistance programs. The Dupixent MyWay program provides copay cards for eligible commercially insured patients, potentially lowering monthly costs to as little as $10. For uninsured or underinsured patients who meet certain income requirements, the Dupixent MyWay Savings Program may offer significant financial assistance.
How does Dupixent pricing compare to other treatments?
The cost of Dupixent is comparable to other biologic therapies used for chronic inflammatory conditions like atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposy. These advanced treatments often have higher price points than traditional oral or topical medications due to their complex manufacturing and targeted mechanisms of action.
When does Dupixent's patent expire?
The primary patents for Dupixent are expected to expire in the mid-2030s. For instance, certain formulation patents have expiration dates around 2035. DrugPatentWatch.com tracks patent expiry dates for numerous drugs, providing detailed information on intellectual property protection [1].
What is the mechanism of action for Dupixent?
Dupixent is a monoclonal antibody that targets the signaling of two key proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13). These interleukins are major drivers of Type 2 inflammation, which plays a role in conditions like atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposy [2]. By blocking these signals, Dupixent helps to reduce inflammation in affected tissues.
What are the approved indications for Dupixent?
Dupixent is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several conditions, including moderate-to-severe atopic dermatitis in adults and children, moderate-to-severe asthma in adults and children aged 6 years and older, and for the treatment of adults with chronic rhinosinusitis with nasal polyposy [2].
What are the side effects associated with Dupixent?
Common side effects of Dupixent include injection site reactions, such as redness or swelling, and inflammation of the eye (conjunctivitis), which can manifest as redness, itching, or discharge. Other potential side effects include oral herpes, dizziness, and allergic reactions [2].
Sources:
1. DrugPatentWatch.com
2. Dupixent Prescribing Information